ADI-001 Cmax and D28 persistent exposure were comparable to, or exceeded, those demonstrated by alternative allogeneic CAR T therapies and approved autologous CD19 CAR T therapies. Favorable clinical responses were also associated with higher mean and median peak of ADI-001 cells.
The secondary objectives for Parts 1, 2 and 3 include PK, immunogenicity, and antitumor activity of ADI-001 monotherapy or in combination with IL-2. This study is currently enrolling in 4 U.S. sites (NCT04735471).